Anxo Pharmaceutical Flags Its Pulmonary Fibrosis P4 Generic Drug in the Middle East as FDA Accepts ANDA Review

Anxo Pharmaceutical, a specialist in drug delivery technology, announced on the 30th that its pulmonary fibrosis P4 generic drug, NTN, developed jointly with domestic partners, has not only successfully signed licensing and distribution agreements for the Middle East market, but also received FDA acceptance for review of its Abbreviated New Drug Application (ANDA). Once NTN is launched, Anxo will benefit from sales revenue sharing.